<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Pharming Group Nv — News on 6ix</title>
    <link>https://6ix.com/company/pharming-group-nv-1</link>
    <description>Latest news and press releases for Pharming Group Nv on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 16 Apr 2026 06:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/pharming-group-nv-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d54a92beedb30cb6f766c5.webp</url>
      <title>Pharming Group Nv</title>
      <link>https://6ix.com/company/pharming-group-nv-1</link>
    </image>
    <item>
      <title>Pharming Group announces the 2026 Annual General Meeting of Shareholders</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-announces-the-2026-annual-general-meeting-of-shareholders-1</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-announces-the-2026-annual-general-meeting-of-shareholders-1</guid>
      <pubDate>Thu, 16 Apr 2026 06:00:00 GMT</pubDate>
      <description>Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company’s 2026 Annual General Meeting of Shareholders (the “AGM”) will be held on Thursday May 28, 2026, at 14:00 CET. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company’s website under Investors/Shareholder Meetings. The agenda of the AGM includes the proposal to appoint KPM</description>
    </item>
    <item>
      <title>Pharming Group to participate in April investor conferences</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-to-participate-in-april-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-to-participate-in-april-investor-conferences</guid>
      <pubDate>Tue, 07 Apr 2026 06:00:00 GMT</pubDate>
      <description>Leiden, the Netherlands, April 7, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences in the month of April: 25th Annual Needham Virtual Healthcare Conference, April 13, 2026Fabrice Chouraqui, Chief Executive Officer, and Anurag Relan, Chief Medical Officer, will present on Monday, April 13 at 08:45 am ET/14:45 CET. A live webcast and replay of the presentation will be available</description>
    </item>
    <item>
      <title>Pharming Group announces the filing of its 2025 Annual Report and Form 20-F</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-announces-the-filing-of-its-2025-annual-report-and-form-20-f-18</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-announces-the-filing-of-its-2025-annual-report-and-form-20-f-18</guid>
      <pubDate>Thu, 02 Apr 2026 05:00:00 GMT</pubDate>
      <description>Leiden, the Netherlands, April 2, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended December 31, 2025. The Annual Report is available at annualreport.pharming.com and under Investors/Financial documents on the Pharming.com website. The Company also announced the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC). The 2025 Annual Report o</description>
    </item>
    <item>
      <title>Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-receives-positive-chmp-opinion-for-joenjar-leniolisib-for-the-treatment-of-apds-in-adult-and-pediatric-patients-12-years-and-older-1</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-receives-positive-chmp-opinion-for-joenjar-leniolisib-for-the-treatment-of-apds-in-adult-and-pediatric-patients-12-years-and-older-1</guid>
      <pubDate>Fri, 27 Mar 2026 06:00:00 GMT</pubDate>
      <description>If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based on Phase II/III clinical data demonstrating statistically significant impact on measures of immune dysregulation and immunodeficiencyFinal European Commission decision expected in Q2 2026 Leiden, the Netherlands, March 27, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURON</description>
    </item>
    <item>
      <title>Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-announces-approval-of-joenjar-leniolisib-in-japan-for-the-treatment-of-apds-in-patients-aged-4-years-and-older-1</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-announces-approval-of-joenjar-leniolisib-in-japan-for-the-treatment-of-apds-in-patients-aged-4-years-and-older-1</guid>
      <pubDate>Tue, 24 Mar 2026 06:00:00 GMT</pubDate>
      <description>First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Approval is based on positive Phase III data from multinational and Japanese studies in patients aged 12 years and older and a multinational pediatric study in children aged 4 to 11 yearsFirst approval of Joenja covering children aged 4 to 11 with APDS Leiden, the Netherlands, March 24, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announ</description>
    </item>
    <item>
      <title>Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-reports-fourth-quarter-and-full-year-2025-financial-results-delivering-strong-revenue-growth-and-profitability-with-positive-cash-flow-1</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-reports-fourth-quarter-and-full-year-2025-financial-results-delivering-strong-revenue-growth-and-profitability-with-positive-cash-flow-1</guid>
      <pubDate>Thu, 12 Mar 2026 06:00:00 GMT</pubDate>
      <description>Full year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST® and rising demand for Joenja® (leniolisib) Fourth quarter 2025 total revenues increased by 15% to US$106.5 million, compared to the fourth quarter 2024RUCONEST® full year revenue increased by 26% to US$317.9 million and fourth quarter revenue increased by 9% to US$86.7 millionJoenja® revenue increased by 29% to US$58.2 million and fourth quarter revenue increased by 53% to US$19.8 millionA</description>
    </item>
    <item>
      <title>Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-march-12-1</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-march-12-1</guid>
      <pubDate>Thu, 26 Feb 2026 07:00:00 GMT</pubDate>
      <description>Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and full year 2025 and provide a business update on Thursday, March 12, 2026. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/08:30 am EDT. To participate in the conference call or to watch the live webcast,</description>
    </item>
    <item>
      <title>Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference-1</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference-1</guid>
      <pubDate>Tue, 17 Feb 2026 07:00:00 GMT</pubDate>
      <description>Leiden, the Netherlands, February 17, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held virtually on February 25-26, 2026. Fabrice Chouraqui, Chief Executive Officer, and Anurag Relan, M.D., Chief Medical Officer, will present on Wednesday, February 25 at 12:40pm ET/18:40 CET. A live webcast and replay of the presentation will be made avai</description>
    </item>
    <item>
      <title>Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-announces-2026-financial-guidance-and-highlights-rare-disease-pipeline-at-investor-day</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-announces-2026-financial-guidance-and-highlights-rare-disease-pipeline-at-investor-day</guid>
      <pubDate>Tue, 03 Feb 2026 06:00:00 GMT</pubDate>
      <description>Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program2026 total revenue guidance of US$405 – US$425 million (8% to 13% growth)2026 total operating expense guidance of US$330 – US$335 millionInvestor Day will be webcast today starting at 10:00 am EST (16:00 CE</description>
    </item>
    <item>
      <title>Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-receives-complete-response-letter-from-us-fda-for-snda-for-joenjar-leniolisib-in-children-aged-4-to-11-years-with-apds</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-receives-complete-response-letter-from-us-fda-for-snda-for-joenjar-leniolisib-in-children-aged-4-to-11-years-with-apds</guid>
      <pubDate>Sun, 01 Feb 2026 20:17:00 GMT</pubDate>
      <description>Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. The FDA raise</description>
    </item>
    <item>
      <title>Pharming Group reports preliminary 2025 revenues and announces Investor Day</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-reports-preliminary-2025-revenues-and-announces-investor-day</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-reports-preliminary-2025-revenues-and-announces-investor-day</guid>
      <pubDate>Thu, 08 Jan 2026 06:00:00 GMT</pubDate>
      <description>Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET). Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately</description>
    </item>
    <item>
      <title>Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-to-participate-in-oppenheimer-movers-in-rare-disease-summit</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-to-participate-in-oppenheimer-movers-in-rare-disease-summit</guid>
      <pubDate>Mon, 08 Dec 2025 07:00:00 GMT</pubDate>
      <description>Leiden, the Netherlands, December 8, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York City. This invitation-only event brings together innovative companies and investors focused on rare diseases. Anurag Relan, M.D., Chief Medical Officer of Pharming, will participate in a fireside chat focused on the hereditary angioedema (HAE) market at 1:50 pm ET /</description>
    </item>
    <item>
      <title>Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-reports-third-quarter-2025-financial-results-with-significant-growth-in-revenue-profitability-and-cash-flow</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-reports-third-quarter-2025-financial-results-with-significant-growth-in-revenue-profitability-and-cash-flow</guid>
      <pubDate>Thu, 06 Nov 2025 06:00:00 GMT</pubDate>
      <description>Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patients and prescribersJoenja® (leniolisib) third quarter revenue increased by 35% to US$15.1 million, compared to third quarter 2024, reflecting strong growth in patients on therapy FDA granted priority review of sNDA for leniolisib for children aged 4 to 11 years</description>
    </item>
    <item>
      <title>Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-to-participate-in-fireside-chat-at-jefferies-global-healthcare-conference-in-london</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-to-participate-in-fireside-chat-at-jefferies-global-healthcare-conference-in-london</guid>
      <pubDate>Thu, 30 Oct 2025 07:00:00 GMT</pubDate>
      <description>Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare Conference in London, UK, on November 17-20, 2025. Fabrice Chouraqui, Chief Executive Officer, will participate in a Fireside Chat Q&amp;A session on Wednesday, November 19 at 10:00 GMT/11:00 CET. A live webcast and replay of the presentation can be found in the “Upcoming Events” and “News” sections</description>
    </item>
    <item>
      <title>Pharming Group to report third quarter 2025 financial results and provide business update on November 6</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-6</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-6</guid>
      <pubDate>Thu, 23 Oct 2025 06:00:00 GMT</pubDate>
      <description>Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a business update on Thursday, November 6, 2025. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/07:30 am ET. To participate in the conference call or to watch the live webcast, please register in advance using</description>
    </item>
    <item>
      <title>Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-announces-presentations-at-2025-acaai-annual-scientific-meeting-showcasing-new-data-across-rare-disease-portfolio</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-announces-presentations-at-2025-acaai-annual-scientific-meeting-showcasing-new-data-across-rare-disease-portfolio</guid>
      <pubDate>Mon, 20 Oct 2025 06:00:00 GMT</pubDate>
      <description>Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at the American College of Allergy, Asthma &amp; Immunology (ACAAI) 2025 Annual Scientific Meeting taking place in Orlando, Florida on November 6-10. Five posters will present positive new clinical, economic, and comparative data for RUCONEST® (recombinant C1 esterase inhibitor) and its role in on-demand her</description>
    </item>
    <item>
      <title>Pharming Group provides update on previously announced G&amp;A expense reduction plan</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-provides-update-on-previously-announced-ganda-expense-reduction-plan</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-provides-update-on-previously-announced-ganda-expense-reduction-plan</guid>
      <pubDate>Mon, 06 Oct 2025 15:35:00 GMT</pubDate>
      <description>Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restructuring is aligned with our previously announced plan to reduce general and administrative (G&amp;A) expenses to optimize capital allocation across the organization. The restructuring includes a redesign of Pharming’s organizational structure and a 20% net reducti</description>
    </item>
    <item>
      <title>Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-announces-us-fda-acceptance-and-priority-review-of-supplemental-new-drug-application-for-leniolisib-in-children-with-apds-aged-4-to-11-years</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-announces-us-fda-acceptance-and-priority-review-of-supplemental-new-drug-application-for-leniolisib-in-children-with-apds-aged-4-to-11-years</guid>
      <pubDate>Wed, 01 Oct 2025 05:00:00 GMT</pubDate>
      <description>If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based on positive data from multinational Phase III study in children aged 4 to 11 years with APDSPDUFA target action date of January 31, 2026 Leiden, the Netherlands, October 1, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Dr</description>
    </item>
    <item>
      <title>Pharming Group promoted to the Euronext AMX® index</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-promoted-to-the-euronext-amxr-index</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-promoted-to-the-euronext-amxr-index</guid>
      <pubDate>Wed, 10 Sep 2025 05:00:00 GMT</pubDate>
      <description>Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from September 22, 2025. Euronext Amsterdam announced the results of its review of the AMX index, which comprises 25 companies based on free-float market capitalization and liquidity. This marks Pharming’s return to the AMX index, reflecting the Company’s s</description>
    </item>
    <item>
      <title>Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
      <link>https://6ix.com/company/pharming-group-nv-1/news/pharming-group-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/pharming-group-nv-1/news/pharming-group-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference</guid>
      <pubDate>Wed, 03 Sep 2025 06:00:00 GMT</pubDate>
      <description>Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025. Fabrice Chouraqui, Chief Executive Officer, will present on Monday, September 8 at 1:30pm EDT/19:30 CEST. A live webcast and replay of the presentation can be found in the “Upcoming Events” and “News” sections of Pharming’s websi</description>
    </item>
  </channel>
</rss>